AstraZeneca is investing $2 billion in Summit Therapeutics, according to both STAT and BioPharma Dive. The investment is tied to development of ivonescimab, an experimental bispecific antibody targeting PD-1 and VEGF, and will support testing the drug in combination with AstraZeneca’s own therapies.
BioPharma Dive provides additional detail: the investment is an equity stake that gives AstraZeneca a “seat at the table” in the PD-1/VEGF push, but does not hand the pharmaceutical company any ownership rights over Summit. STAT’s report confirms the $2 billion figure but does not describe the deal’s structure.
The two outlets agree on the headline investment amount, while BioPharma Dive adds specifics about the collaboration’s scope. Neither source provides clinical efficacy data for ivonescimab, though the deal signals continued interest in bispecific cancer immunotherapies.